Drug intelligence / Profile preview

TX1111

Development stage: Preclinical
Lead developer: University of Illinois College of Medicine Peoria
Modality: Peptides

Overview

TX1111 is a peptide homologue of Topoisomerase-1 (TOP1) designed to sensitize pancreatic cancer cells, specifically pancreatic ductal adenocarcinoma (PDAC), to the chemotherapy agent gemcitabine. Developed by researchers at the University of Illinois College of Medicine at Peoria, TX1111 works by mimicking a specific domain of the TOP1 enzyme, potentially interfering with DNA repair or replication processes that contribute to gemcitabine resistance. In preclinical studies, TX1111 has demonstrated the ability to enhance the cytotoxic effects of gemcitabine in drug-resistant pancreatic cancer cell lines, offering a potential strategy to overcome chemoresistance in this lethal malignancy.

Other names: peptide homologue of Topoisomerase-1

Targets

TOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on TX1111.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TX1111.

Explore the full profile